News

Articles

08/12/2022

ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs

07/27/2022

Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle

07/21/2022

Opus Genetics Expands its Leadership Team

07/11/2022

Opus Genetics to Present at OIS Retina Innovation Summit 2022

05/11/2022

Opus Genetics Appoints Jennifer Hunt Chief Development Officer

02/15/2022

Opus Genetics Appoints Brian Leising Vice President, Manufacturing

02/11/2022

ProQR Announces Top-Line Results from Phase 2/3 Illuminate Trial of Sepofarsen in CEP290-mediated LCA10

01/05/2022

SalioGen Therapeutics Closes $115 Million Oversubscribed Series B Financing to Advance Gene Coding™ – A New Category of Genetic Medicine

12/16/2021

ProQR Announces First Patients Dosed in Phase 2/3 Pivotal Trials of QR-421a for USH2A Mediated Retinitis Pigmentosa

12/09/2021

SparingVision Strengthens Leadership Team with the Appointment of Dr Mehdi Gasmi as Chief Operating Officer

12/06/2021

Gyroscope Therapeutics Announces Appointment of Tony Adamis to Board of Directors

12/02/2021

Startup spotlight: Opus Genetics, with $19M, works to advance cures for blinding retinal diseases

11/30/2021

Opus Genetics announces licensing of third program for inherited retinal disease

11/11/2021

Opus Genetics Announces Agreement with Massachusetts Eye and Ear and Harvard Medical School to License Third Program for Inherited Retinal Disease

11/08/2021

Opus Genetics Announces Presence at Eyecelerator@AAO 2021

10/28/2021

Pfizer, Novartis sign on to accelerate gene therapies for rare diseases with US agencies

10/20/2021

Opus Genetics Announces Two Key Leadership Appointments

10/13/2021

Intellia beefs up ocular pipeline with 10% stake in SparingVision

10/13/2021

Intellia Therapeutics and SparingVision Announce Strategic Collaboration to Develop Novel Ocular Therapies Using CRISPR/Cas9 Technology

10/04/2021

ProQR Appoints Theresa Heggie as Chief Commercial Officer

09/22/2021

Luxturna inventor Jean Bennett starts a new gene therapy company to tackle rare diseases left behind by pharma, VCs

07/29/2021

To Get New Treatments Across the Finish Line, a Funder Fighting Blindness Turns to Investing

07/12/2021

Atsena Therapeutics Appoints Jennifer Wellman to Board of Directors

06/04/2021

Venture philanthropy: The secret weapon for unlocking biomedical research's full life-changing potential

05/18/2021

Vedere Bio II Launches with $77 Million Series A Financing to Develop Next Generation Ocular Gene Therapies

03/24/2021

ProQR Announces Positive Results from Clinical Trial of QR-421a in Usher Syndrome and Plans to Start Pivotal Trials

03/19/2021

SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

02/04/2021

Dr Daniel C. Chung appointed as Chief Medical Officer of SparingVision

01/29/2021

Renowned Pioneers in Ophthalmology Join SparingVision’s Scientific Advisory Board

12/16/2020

Atsena Therapeutics Raises $55 Million Series A Financing to Advance LCA1 Gene Therapy Clinical Program, Two Preclinical Assets, and Novel Capsid Development for Ocular Diseases

11/09/2020

Stargazer Pharmaceuticals, Inc. Announces $57 Million Series A Financing and Initiation of a Phase 2a Clinical Study of STG-001 in Stargardt Disease Patients

10/29/2020

Novartis Acquires Vedere Bio, a Novel Optogenetics AAV Gene Therapy Company

10/21/2020

SparingVision Raises €44.5 Million and Appoints Stéphane Boissel as Chief Executive Officer

07/29/2020

Atsena Therapeutics acquires exclusive rights to Gene Therapy for GUCY2D-associated Leber Congenital Amaurosis

05/18/2020

Nacuity Pharmaceuticals Announces Initiation of SLO-RP (Safety and Efficacy of NPI-001 Tablets versus PLacebO for Treatment of Retinitis Pigmentosa Associated with Usher Syndrome) Phase 1/2 Clinical Trial

04/28/2020

CheckedUp Launches Virtual Visits, Advanced Telehealth Platform for Specialty Care

03/31/2020

ProQR Announces Positive Findings From an Interim Analysis in the Phase 1/2 trial of QR-421a for Usher Syndrome and Provides Business Update

07/09/2019

SparingVision Awarded at EIC Accelerator Program (H2020 SME Instrument Phase 2), Securing Funding of €2.5 Million

03/11/2019

ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

07/12/2017

SparingVision Formed to Advance Sight-Saving Protein for RP

Load More

Press Releases

07/21/2022

RD Fund Announces New Chair, and Expansion of Board of Directors

06/21/2022

Foundation Fighting Blindness Announces Leadership Changes

06/15/2022

Nacuity Pharmaceuticals Announces $16.5 Million Series B Financing Led by Foundation Fighting Blindness & RD Fund

03/08/2022

Foundation Fighting Blindness and InformedDNA Partner to Engage and Screen Patients for ProQR’s Pivotal Usher Syndrome and Retinitis Pigmentosa Clinical Trials

01/19/2022

Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer

01/06/2022

RD Fund Announces Series B Financing Behind SalioGen Therapeutics

10/28/2021

RD Fund Announces Fundraising Efforts Underway for RD Fund 2

10/04/2021

RD Fund Appoints Tony Adamis, MD to Board of Directors

09/22/2021

RD Fund Launches Opus Genetics with $19M Seed Funding to Advance Gene Therapy Treatments for Blinding Conditions

10/23/2018

Foundation Fighting Blindness Launches Retinal Degeneration Fund With More Than $70 million of Initial Funding

02/12/2018

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A

01/18/2018

Foundation Fighting Blindness Supporting Clinical Development of NACA, Promising New Drug for Many Forms of RP

Load More